Total Payments
$7,398
2024 Payments
$18.09
Companies
2
Transactions
22
Medicare Patients
524
Medicare Billing
$216,043
Payment Breakdown by Category
Consulting$5,020 (67.9%)
Research$1,234 (16.7%)
Travel$816.92 (11.0%)
Food & Beverage$308.85 (4.2%)
Education$18.09 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $5,020 | 1 | 67.9% |
| Unspecified | $1,234 | 12 | 16.7% |
| Travel and Lodging | $816.92 | 3 | 11.0% |
| Food and Beverage | $308.85 | 5 | 4.2% |
| Education | $18.09 | 1 | 0.2% |
Payments by Type
General
$6,164
10 transactions
Research
$1,234
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Biogen, Inc. | $7,380 | 21 | $0 (2018) |
| Merck Sharp & Dohme LLC | $18.09 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18.09 | 1 | Merck Sharp & Dohme LLC ($18.09) |
| 2018 | $7,380 | 21 | Biogen, Inc. ($7,380) |
All Payment Transactions
22 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/25/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 11/28/2018 | Biogen, Inc. | — | Consulting Fee | Cash or cash equivalent | $5,020.00 | General |
| 10/16/2018 | Biogen, Inc. | — | Travel and Lodging | Cash or cash equivalent | $356.32 | General |
| 10/16/2018 | Biogen, Inc. | — | Food and Beverage | Cash or cash equivalent | $39.94 | General |
| 10/16/2018 | Biogen, Inc. | — | Food and Beverage | Cash or cash equivalent | $32.62 | General |
| 10/16/2018 | Biogen, Inc. | — | Food and Beverage | Cash or cash equivalent | $20.71 | General |
| 10/15/2018 | Biogen, Inc. | — | Travel and Lodging | Cash or cash equivalent | $271.60 | General |
| 10/15/2018 | Biogen, Inc. | — | Travel and Lodging | Cash or cash equivalent | $189.00 | General |
| 10/15/2018 | Biogen, Inc. | — | Food and Beverage | Cash or cash equivalent | $86.30 | General |
| 09/07/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $61.47 | Research |
| Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | ||||||
| 09/07/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $58.99 | Research |
| Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | ||||||
| 09/07/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $55.50 | Research |
| Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | ||||||
| 09/07/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $29.84 | Research |
| Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | ||||||
| 09/06/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $133.00 | Research |
| Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | ||||||
| 09/06/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $64.84 | Research |
| Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | ||||||
| 09/06/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $59.69 | Research |
| Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | ||||||
| 09/06/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $59.10 | Research |
| Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | ||||||
| 09/05/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $302.26 | Research |
| Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | ||||||
| 09/05/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $163.40 | Research |
| Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | ||||||
| 09/05/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $134.97 | Research |
| Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | ||||||
| 09/05/2018 | Biogen, Inc. | — | — | Cash or cash equivalent | $110.99 | Research |
| Study: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | ||||||
| 01/24/2018 | Biogen, Inc. | — | Food and Beverage | In-kind items and services | $129.28 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction | Biogen, Inc. | $1,234 | 12 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 120 | 274 | $220,844 | $45,071 |
| 2022 | 3 | 140 | 332 | $266,234 | $56,763 |
| 2021 | 2 | 144 | 377 | $310,197 | $65,695 |
| 2020 | 2 | 120 | 266 | $220,528 | $48,514 |
Total Patients
524
Total Services
1,249
Medicare Billing
$216,043
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 95 | 239 | $210,614 | $42,727 | 20.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 25 | 35 | $10,230 | $2,345 | 22.9% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 95 | 281 | $243,571 | $51,937 | 21.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 16 | 16 | $12,688 | $2,704 | 21.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 29 | 35 | $9,975 | $2,122 | 21.3% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 120 | 334 | $297,536 | $63,021 | 21.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 24 | 43 | $12,661 | $2,674 | 21.1% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 107 | 239 | $212,607 | $46,776 | 22.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 13 | 27 | $7,921 | $1,737 | 21.9% |
About Matthew Bevers, MD, PHD
Matthew Bevers, MD, PHD is a Neurology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/08/2010. The National Provider Identifier (NPI) number assigned to this provider is 1114247582.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Matthew Bevers, MD, PHD has received a total of $7,398 in payments from pharmaceutical and medical device companies, with $18.09 received in 2024. These payments were reported across 22 transactions from 2 companies. The most common payment nature is "Consulting Fee" ($5,020).
As a Medicare-enrolled provider, Bevers has provided services to 524 Medicare beneficiaries, totaling 1,249 services with total Medicare billing of $216,043. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Boston, MA
- Active Since 06/08/2010
- Last Updated 01/07/2026
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1114247582
Products in Payments
- WELIREG (Drug) $18.09
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Boston
Christopher Wright, Md, MD
Neurology — Payments: $2.0M
Neurology $2.0M
Dr. Alfred Sandrock, Md Phd, MD PHD
Neurology — Payments: $1.2M
Neurology $1.2M
Thomas Scammell, M.d, M.D
Neurology — Payments: $598,925
Neurology $598,925
Patrick Wen, Md, MD
Neurology — Payments: $583,963
Neurology $583,963
Dr. Michael Levy, M.d., Ph.d, M.D., PH.D
Neurology — Payments: $519,354
Neurology $519,354
Roy Freeman, M.d, M.D
Neurology — Payments: $489,143
Neurology $489,143